Özgecan Dülgar1, Şennur İlvan2, Zeynep Hande Turna3. 1. Departmant of Medical Oncology, İstanbul Medeniyet University Göztepe Training and Research Hospital, İstanbul, Turkey. 2. Deptartment of Pathology, İstanbul University-Cerrahpaşa, Cerrahpasa School of Medicine, İstanbul, Turkey. 3. Department of Medical Oncology, İstanbul University-Cerrahpaşa, Cerrahpasa School of Medicine, İstanbul, Turkey.
Abstract
OBJECTIVE: Triple-negative-breast-cancer (TNBC) is a very heterogenous disease some of which are very aggressive and have poor prognosis. No targeted therapy is available. Immune response and tumor-infiltrating lymphocytes (TIL) can be related to longer disease-free survival (DFS) and overall survival (OS) in TNBC. Family history of cancer can be related poor prognosis, irrespective of genetic mutation. MATERIALS AND METHODS: Pathology reports and files of 167 patients operated for TNBC were assessed retrospectively. The effects of lymphocyte infiltration, family history of cancer and other tumor characteristics on prognosis were evaluated. Data of 137 patients was included in statistical analysis. RESULTS: Univariate-analysis revealed that stage, size of tumor, histological subtype, number of infiltrated axillary lymph-nodes, lymphatic and vascular invasion, choice of adjuvant/neoadjuvant chemotherapy, family history of cancer has a statistically significant effect on DFS. Increase in density of lymphocyte infiltration of tumor has also better a prognostic effect on DFS (p=0.02). In multivariate-analysis, only tumor size and choice of adjuvant/neoadjuvant chemotherapy are found to have statistically significant effect. CONCLUSION: Tumor lymphocyte infiltration was found to have a statistically significant better prognostic effect on DFS but not on OS of patients with operated TNBC. This result can be due to variability of therapies administered after recurrence and other confounding factors that may have an effect on OS.
OBJECTIVE: Triple-negative-breast-cancer (TNBC) is a very heterogenous disease some of which are very aggressive and have poor prognosis. No targeted therapy is available. Immune response and tumor-infiltrating lymphocytes (TIL) can be related to longer disease-free survival (DFS) and overall survival (OS) in TNBC. Family history of cancer can be related poor prognosis, irrespective of genetic mutation. MATERIALS AND METHODS: Pathology reports and files of 167 patients operated for TNBC were assessed retrospectively. The effects of lymphocyte infiltration, family history of cancer and other tumor characteristics on prognosis were evaluated. Data of 137 patients was included in statistical analysis. RESULTS: Univariate-analysis revealed that stage, size of tumor, histological subtype, number of infiltrated axillary lymph-nodes, lymphatic and vascular invasion, choice of adjuvant/neoadjuvant chemotherapy, family history of cancer has a statistically significant effect on DFS. Increase in density of lymphocyte infiltration of tumor has also better a prognostic effect on DFS (p=0.02). In multivariate-analysis, only tumor size and choice of adjuvant/neoadjuvant chemotherapy are found to have statistically significant effect. CONCLUSION: Tumor lymphocyte infiltration was found to have a statistically significant better prognostic effect on DFS but not on OS of patients with operated TNBC. This result can be due to variability of therapies administered after recurrence and other confounding factors that may have an effect on OS.
Authors: M Elizabeth H Hammond; Daniel F Hayes; Antonio C Wolff; Pamela B Mangu; Sarah Temin Journal: J Oncol Pract Date: 2010-06-23 Impact factor: 3.840
Authors: Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-10-29 Impact factor: 508.702
Authors: Brian Ruffell; Alfred Au; Hope S Rugo; Laura J Esserman; E Shelley Hwang; Lisa M Coussens Journal: Proc Natl Acad Sci U S A Date: 2011-08-08 Impact factor: 11.205
Authors: Y Wang; F Ylera; M Boston; S-G Kang; J L Kutok; A J P Klein-Szanto; R P Junghans Journal: Breast Cancer Res Treat Date: 2007-03-28 Impact factor: 4.872
Authors: Elena García-Martínez; Ginés Luengo Gil; Asunción Chaves Benito; Enrique González-Billalabeitia; María Angeles Vicente Conesa; Teresa García García; Elisa García-Garre; Vicente Vicente; Francisco Ayala de la Peña Journal: Breast Cancer Res Date: 2014-11-29 Impact factor: 6.466
Authors: Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544